How Long Does SLU-PP-332 Stay in Your System? What the Literature Reports

Short answer first: the published record on SLU-PP-332 does not contain a human half-life, a clearance curve, or a validated detection window. The papers that describe the compound are pharmacology papers — they characterised what the molecule did at estrogen-related receptors (ERRα, ERRβ, ERRγ) in cells and animals, not how long it persisted in blood or tissue in people. Everything below separates compound-specific findings from general pharmacology principles, and labels which is which.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine, supplement, or investigational compound.

What the SLU-PP-332 literature actually measured

The primary characterisation paper described a synthetic ERRα/β/γ agonist that induced an ERRα-dependent acute aerobic exercise response and enhanced exercise capacity in preclinical models, and the study framed the compound as an exercise mimetic acting through ERR transcriptional programs (PMID 36988910). A later cardiovascular paper reported that novel pan-ERR agonists ameliorated heart failure in preclinical models through enhancing cardiac fatty acid metabolism and mitochondrial function (PMID 37961903). Both of those reports are pharmacodynamic — they describe effect, not exposure.

Neither of those two papers, in title or abstract scope, reported a plasma half-life, an area-under-the-curve value, a volume of distribution, a renal-versus-hepatic elimination split, or a terminal detection time (PMID 36988910, PMID 37961903). That absence is the single most important fact on this page. Any specific number circulating online for "SLU-PP-332 half-life" is not traceable to those publications.

Why peptide clearance rules do not apply here

SLU-PP-332 is a synthetic small molecule that binds the ERR nuclear receptor family; it is not a peptide, and it is not built from an amino-acid chain. Structural work on the target supports that framing: a molecular simulation study uncovered a novel binding trench in ERRα and examined how ligands occupy the receptor pocket (PMID 40083629). Small molecules and peptides are eliminated by different machinery — peptides are typically broken down by peptidases and cleared renally, while small molecules more often depend on hepatic enzymatic metabolism and transporter-mediated excretion. For the general framework on how injected peptides are cleared, see how long peptides stay in your system; those principles are informative background but they do not predict small-molecule ERR agonist kinetics.

Half-life, clearance, and detection: three different questions

These three terms are often collapsed into one in casual discussion, and that is where most confusion about "how long it stays in your system" begins.

Why a receptor agonist's effects can outlast its presence

ERRs are nuclear receptors that regulate gene transcription, so the biological consequence of binding is not the same as the chemical presence of the ligand. Research on this receptor family showed that thyroid hormone receptor and ERRα coordinately regulated mitochondrial fission, mitophagy, biogenesis, and function — processes that unfold over hours to days rather than minutes (PMID 29945885). Separately, researchers reported that Kruppel-like factor 4 was critical for transcriptional control of cardiac mitochondrial homeostasis, illustrating that mitochondrial gene programs in the heart are governed by transcription-factor networks with their own timescales (PMID 26241060).

The practical implication of those two reports is conceptual, not numerical: a compound can be gone from plasma while the transcriptional program it initiated is still resolving (PMID 29945885). "How long does it stay in your system" and "how long does anything change" are therefore different questions with different answers, and only the second has been approached at all in the SLU-PP-332 literature (PMID 36988910).

Factors that change clearance — general pharmacology, not compound-specific data

The following factors are drawn from general pharmacology rather than from any SLU-PP-332 pharmacokinetic study, because no such study appears in the verified literature. They are listed to explain why exposure varies between individuals and between species, not to estimate a number.

• Route of administration. Oral, intraperitoneal, and injected routes produce different absorption profiles and different first-pass exposure.
• Hepatic metabolic capacity. Small molecules are commonly processed by liver enzymes; liver function and enzyme-inducing or enzyme-inhibiting co-administered drugs alter that rate.
• Renal function. Excretion of parent compound and metabolites depends on glomerular filtration and tubular transport.
• Protein binding and tissue distribution. Highly bound or highly lipophilic molecules can show longer terminal phases because tissue depots release slowly.
• Species differences. Rodent metabolic rates differ substantially from human ones, so animal exposure data do not translate directly.
• Repeat versus single exposure. Accumulation depends on dosing interval relative to half-life — a ratio that cannot be calculated here because the half-life was not published.

Receptor-level context

ERR signalling is not confined to muscle. Research reported that ERRα and the coactivator PGC-1β acted as effectors of IFN-γ-induced host defence (PMID 17671090), that ERRγ suppression by Sirt6 alleviated cholestatic liver injury and fibrosis in a liver model (PMID 32701506), and that estrogen receptors and estrogen-related receptors are expressed and functional in the brain with associations described in Alzheimer's disease research (PMID 37469978). Broad receptor distribution matters for the exposure question because distribution into multiple tissues can create a longer terminal elimination phase than a plasma snapshot suggests (PMID 32701506).

Detectability and drug testing: what is and is not tested for

Stated plainly:

1. Standard workplace and clinical urine panels do not screen for SLU-PP-332. Those panels are immunoassays built around defined drug classes — opioids, amphetamines, cannabinoids, cocaine metabolites, benzodiazepines, phencyclidine and similar analytes. A synthetic ERR agonist is not one of the targeted analytes and does not cross-react by design.
2. Routine blood chemistry does not identify it either. Liver panels, lipid panels and metabolic panels measure physiology, not specific xenobiotics.
3. Anti-doping laboratories work differently. Accredited sport laboratories use high-resolution liquid chromatography–mass spectrometry and can develop targeted methods for emerging compounds, including substances with no marketing approval in any jurisdiction. The World Anti-Doping Agency publishes its Prohibited List annually, including a category for non-approved substances; athletes subject to testing generally consult the current published list and their national anti-doping organisation for status questions.
4. No validated detection window exists in the verified literature. Without a published assay and excretion study, any stated "detection time" for SLU-PP-332 is an assumption rather than a measurement.

SLU-PP-332 has no approved medical product anywhere; the material described in these publications was used as a research chemical in laboratory experiments (PMID 36988910).

Tolerability and Adverse Events: What Studies Report

The verified literature on this compound is preclinical, and the reports centre on efficacy endpoints. Researchers reported that pan-ERR agonists ameliorated heart failure through enhanced cardiac fatty acid metabolism and mitochondrial function in preclinical heart failure models (PMID 37961903), and the characterisation study reported an ERRα-dependent acute aerobic exercise response with enhanced exercise capacity (PMID 36988910). No human safety trial, no toxicology summary, and no long-term adverse-event dataset for SLU-PP-332 appears in this citation set.

Because ERR signalling touches liver, immune and neural tissue (PMID 32701506, PMID 17671090, PMID 37469978), off-target consequences of systemic pan-receptor agonism remain an open research question rather than a settled one.

Comparing with the broader small-molecule and peptide literature

Discussion of autophagy-modulating small molecules in neurological research has catalogued how structurally distinct compounds reach central nervous system targets with very different exposure profiles (PMID 34729301), and medicinal-chemistry work on novel hydrazone derivatives has illustrated how design and in silico analysis precede any exposure characterisation in early compound development (PMID 30887930). Those two reports are not about SLU-PP-332; they are included to show that an early-stage molecule typically has published pharmacology long before it has published human pharmacokinetics (PMID 34729301).

Limitations of the current evidence

• No human study of SLU-PP-332 exposure has been published in this citation set (PMID 36988910).
• Animal pharmacology does not establish human half-life, and the heart failure work reported mechanism and outcome rather than plasma kinetics (PMID 37961903).
• Transcriptional effects documented for the ERR family unfold on a different timescale from drug clearance, so the two should not be read as one number (PMID 29945885).
• Structural modelling of the ERRα pocket describes binding, not duration of systemic exposure (PMID 40083629).

For background on the compound's mechanism and research history, see the overview at SLU-PP-332.

References

• Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (ACS Chemical Biology, 2023)
• Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function (Circulation, 2024)
• Uncovering a novel binding trench in ERRα: insights from molecular simulations (Frontiers in Molecular Biosciences, 2025)
• Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function (Science Signaling, 2018)
• Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis (The Journal of Clinical Investigation, 2015)
• Nuclear receptor ERR alpha and coactivator PGC-1 beta are effectors of IFN-gamma-induced host defense (Genes & Development, 2007)
• ERRγ suppression by Sirt6 alleviates cholestatic liver injury and fibrosis (JCI Insight, 2020)
• Expression and function of estrogen receptors and estrogen-related receptors in the brain and their association with Alzheimer's disease (Frontiers in Endocrinology, 2023)
• Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease (Acta Pharmaceutica Sinica B, 2021)
• Design, Synthesis, Anti-Proliferative, Anti-microbial, Anti-Angiogenic Activity and In Silico Analysis of Novel Hydrazone Derivatives (Anti-Cancer Agents in Medicinal Chemistry, 2019)